πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to X4 Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

losmapimod and FTX-6058

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States.

Tags: FTX-6058, biopharmaceutical, clinical-stage, facioscapulohumeral muscular dystrophy, genetically defined diseases, hemoglobinopathies, losmapimod, sickle cell disease

Symbol: FULC

Recent Price: $4.68

Industry: Biotechnology

CEO: Mr. Alexander C. Sapir

Sector: Healthcare

Employees: 76

Address: 26 Landsdowne Street, Cambridge, MA 02139

Phone: 617 651 8851

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten BΓΆnnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

AVTX-002, AVTX-007, AVTX-801

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

Tags: clinical trials, immuno-oncology, immunology, precision medicine, rare genetic diseases, therapeutics

Symbol: AVTX

Recent Price: $7.80

Industry: Biotechnology

CEO: Dr. Garry A. Neil M.D.

Sector: Healthcare

Employees: 19

Address: 540 Gaither Road, Rockville, MD 20850

Phone: 410 522 8707

Leadership

  • Garry A. Neil, MD, Chairman of the Board and Chief Executive Officer
  • Mittie Doyle, MD, FACR, Chief Medical Officer
  • Chris Sullivan, Chief Financial Officer
  • Paul Varki, Chief Legal Officer
  • Lisa Hegg PhD, Senior Vice President, Program Management and Corporate Infrastructure and Clinical Operations
  • Colleen Matkowski, Senior Vice President, Global Regulatory Affairs and Quality Assurance
  • Dino C. Miano, PhD, Senior Vice President, CMC and Technical Operations
  • June Almenoff, MD, PhD, President and Chief Medical Officer
  • Mitchell Chan, Chief Financial Officer
  • Jonathan Goldman, MD, CEO
  • Aaron Kantoff, Managing Partner
  • Gilla Kaplan, PhD, Independent Director
  • Samantha Truex, CEO

Last updated: 2024-12-31

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. logo
Market Cap: Highest
Employees: High

Vimizim

Bio Marin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Their products cater to conditions like mucopolysaccharidosis, phenylketonuria, Batten disease, and more.

Tags: biotechnology, enzyme replacement therapy, healthcare, pharmaceutical, rare diseases

Symbol: BMRN

Recent Price: $65.45

Industry: Biotechnology

CEO: Mr. Alexander Hardy

Sector: Healthcare

Employees: 3401

Address: 770 Lindaro Street, San Rafael, CA 94901

Phone: 415 506 6700

Leadership

  • Mark Enyedy,
  • Alexander Hardy,
  • Elaine J. Heron,
  • G. Eric Davis, Executive Vice President, Chief Legal Officer
  • Greg Friberg, Executive Vice President, Chief Research & Development Officer
  • C. Greg Guyer, Executive Vice President, Chief Technical Officer
  • Cristin Hubbard, Executive Vice President, Chief Commercial Officer
  • Marni Kottle, Executive Vice President, Chief Corporate Affairs Officer
  • Brian R. Mueller, Executive Vice President, Chief Financial Officer
  • James Sabry, Executive Vice President, Chief Business Officer
  • Amy Wireman, Executive Vice President, Chief People Officer
  • Richard A. Meier,
  • Elizabeth McKee Anderson,
  • Barbara Bodem,
  • Athena Countouriotis,
  • Willard H. Dere,
  • Maykin Ho,
  • Robert J. Hombach,
  • David E.I. Pyott,

Last updated: 2024-12-31

Curis, Inc.

Curis, Inc. logo
Market Cap: Lowest
Employees: Lowest

Emavusertib

Curis, Inc. is a biotechnology company focused on discovering and developing drug candidates for treating human cancers, with a range of clinical stage and pipeline products targeting lymphomas, leukemia, and solid tumors.

Tags: biotechnology, cancer treatment, clinical trials, drug development, oncology

Symbol: CRIS

Recent Price: $3.14

Industry: Biotechnology

CEO: Mr. James E. Dentzer

Sector: Healthcare

Employees: 49

Address: Building C, Lexington, MA 02421

Phone: 617 503 6500

Leadership

  • Martyn D. Greenacre, Chair of the Board
  • John Hohneker, M.D., Director
  • Kenneth I. Kaitin, Ph.D., Director
  • Anne E. Borgman, M.D., Director
  • Marc Rubin, M.D., Director
  • James Dentzer, Chief Executive Officer and Director

Last updated: 2024-12-31

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELX-02

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.

Tags: ELX-02, biopharmaceutical, clinical trials, cystic fibrosis, nephropathic cystinosis, rare diseases, ribosome modulation

Symbol: ELOX

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Sumit Aggarwal M.B.A.

Sector: Healthcare

Employees: 18

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 781 577 5300

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. logo
Market Cap: Low
Employees: Medium

XPOVIO

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.

Tags: SINE compounds, XPO1, cancer treatment, nuclear export, oncology, pharmaceutical

Symbol: KPTI

Recent Price: $0.70

Industry: Biotechnology

CEO: Mr. Richard A. Paulson M.B.A.

Sector: Healthcare

Employees: 325

Address: 85 Wells Avenue, Newton, MA 02459

Phone: 617 658 0600

Leadership

  • Richard Paulson, President and Chief Executive Officer
  • James Accumanno, Chief Compliance Officer
  • Brian Austad, Senior Vice President, Pharmaceutical Sciences
  • Sohanya Cheng, Chief Commercial Officer and Head of Business Development
  • Lisa DiPaolo, Chief Human Resources Officer
  • Mike Mano, Senior Vice President and General Counsel
  • Michael Mason, Chief Financial Officer
  • Stuart Poulton, Chief Development Officer
  • Reshma Rangwala, Chief Medical Officer & Head of Research
  • Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
  • Elhan Webb, Senior Vice President, Investor Relations
  • Garen Bohlin, Director
  • Barry E. Greene, Lead Director
  • Mansoor Raza Mirza, MD, Director
  • Richard Paulson, MBA, President and Chief Executive Officer
  • Christy J. Oliger, Director
  • Deepa R. Pakianathan, PhD, Director
  • Chen Schor, Director
  • Zhen Su, MD, MBA, Director

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

LIVMARLI

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare and orphan diseases, with products like LIVMARLI and Volixibat.

Tags: LIVMARLI, Volixibat, biopharmaceutical, orphan diseases, rare diseases

Symbol: MIRM

Recent Price: $41.18

Industry: Biotechnology

CEO: Mr. Christopher Peetz

Sector: Healthcare

Employees: 294

Address: 950 Tower Lane, Foster City, CA 94404

Phone: 650 667 4085

Leadership

  • Chris Peetz, Chief Executive Officer, Mirum Pharmaceuticals
  • Erin Campany, Senior Vice President, Human Resources
  • Eric Bjerkholt, Chief Financial Officer
  • Jean-Luc Girardet, Ph.D., Senior Vice President, Technical Operations
  • Vinita Kumar, Senior Vice President, Quality
  • Lara Longpre, Chief Development Officer
  • Joanne Quan, M.D., Chief Medical Officer
  • Peter Radovich, President & Chief Operating Officer
  • Paul Ross, Chief Compliance Officer
  • Pamela Vig, Ph.D., Chief Scientific Officer and Head of Research
  • Laura Brege, Board Member
  • Patrick Heron, Managing General Partner, Frazier Healthcare Partners
  • Tim Walbert, Former Chairman, President and Chief Executive Officer, Horizon Therapeutics; Sr. Advisor, Amgen
  • Lon Cardon, Ph.D., FMedSci., Board Member
  • William C. Fairey, Board Member
  • Laurent Fischer, M.D., President & Chief Executive Officer, Adverum Biotechnologies
  • Mike Grey, Chairman of the Board, Mirum Pharmaceuticals
  • Saira Ramasastry, MS, MPhil, Managing Partner, Life Sciences Advisory, LLC

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Medium

vonoprazan

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases, with significant advancements in the use of vonoprazan in clinical trials.

Tags: P-CAB, biopharmaceutical, clinical trials, gastrointestinal diseases, vonoprazan

Symbol: PHAT

Recent Price: $8.00

Industry: Biotechnology

CEO: Ms. Terrie J. Curran

Sector: Healthcare

Employees: 452

Address: 100 Campus Drive, Florham Park, NJ 07932

Phone: 877 742 8466

Last updated: 2024-12-31

Quince Therapeutics, Inc.

Quince Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

NOV004

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases, with a bone-targeting drug platform and lead compound NOV004 designed to target bone fracture and disease sites.

Tags: NOV004, biopharmaceutical, biotechnology, bone-targeting, precision therapeutics, rare diseases

Symbol: QNCX

Recent Price: $1.85

Industry: Biotechnology

CEO: Dr. Dirk Thye M.D.

Sector: Healthcare

Employees: 32

Address: 601 Gateway Blvd, South San Francisco, CA 94080

Phone: 415 910 5717

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

Vincerx Pharma, Inc.

Vincerx Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

VIP152

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies to address unmet medical needs for cancer treatment in the United States. Their lead product candidate, VIP152, is a cyclin-dependent kinase-9 inhibitor for advanced cancer.

Tags: biopharmaceutical, cancer treatment, clinical-stage, oncology, therapy development

Symbol: VINC

Recent Price: $0.33

Industry: Biotechnology

CEO: Dr. Ahmed M. Hamdy M.D.

Sector: Healthcare

Employees: 42

Address: 260 Sheridan Avenue, Palo Alto, CA 94306

Phone: 650 800 6676

Last updated: 2024-12-31

Vor Biopharma Inc.

Vor Biopharma Inc. logo
Market Cap: Lowest
Employees: Low

VOR33

Vor Biopharma, Inc. is a clinical-stage company focused on developing engineered hematopoietic stem cell (e HSC) therapies for cancer patients, with a leading product, VOR33, in phase 1/2 trials for AML and other hematological malignancies.

Tags: AML, biotechnology, cancer therapies, e HSC, hematopoietic stem cells

Symbol: VOR

Recent Price: $1.19

Industry: Biotechnology

CEO: Dr. Robert Ang M.B.A., M.D., MBBS

Sector: Healthcare

Employees: 168

Address: 100 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 655 6580

Leadership

  • Robert Ang, MBBS, MBA, President and Chief Executive Officer
  • Eyal Attar, MD, Chief Medical Officer
  • Tirtha Chakraborty, PhD, Chief Scientific Officer
  • Han Choi, MD, LLM, Chief Financial Officer
  • John King, MBA, Chief Commercial Officer and Head of Business Development
  • Tania Philipp, Chief People Officer
  • David Phillips, MBA, Senior Vice President, Head of Quality
  • Samir Vattompadam, MS, Senior Vice President, Portfolio Strategy and Program Management
  • Daniella Beckman, Board of Directors
  • David Lubner, Board of Directors
  • Bill Lundberg, MD, Board of Directors
  • Fouad Namouni, MD, Board Of Directors
  • Matthew R. Patterson, Chairman, Board of Directors
  • Josh Resnick, MD, Board of Directors

Last updated: 2024-12-31

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

mavorixafor

X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases, with its lead product mavorixafor in advanced clinical trials.

Tags: CXCR4, biopharmaceutical, clinical trials, mavorixafor, rare diseases, therapeutics

Symbol: XFOR

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Paula Ragan Ph.D.

Sector: Healthcare

Employees: 127

Address: 61 North Beacon Street, Boston, MA 02134

Phone: 857 529 8300

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31